Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.395 AUD 3.95% Market Closed
Market Cap: 717.9m AUD
Have any thoughts about
Botanix Pharmaceuticals Ltd?
Write Note

Botanix Pharmaceuticals Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Botanix Pharmaceuticals Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash & Cash Equivalents
AU$79.3m
CAGR 3-Years
54%
CAGR 5-Years
76%
CAGR 10-Years
41%
Recce Pharmaceuticals Ltd
ASX:RCE
Cash & Cash Equivalents
AU$4.4m
CAGR 3-Years
-40%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash & Cash Equivalents
AU$110.1m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash & Cash Equivalents
AU$2.6m
CAGR 3-Years
-48%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Probiotec Ltd
ASX:PBP
Cash & Cash Equivalents
AU$12.8m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
34%
Arovella Therapeutics Ltd
ASX:ALA
Cash & Cash Equivalents
AU$12.7m
CAGR 3-Years
24%
CAGR 5-Years
24%
CAGR 10-Years
N/A
No Stocks Found

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
715m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
1.114 AUD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
79.3m AUD

Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents amounts to 79.3m AUD.

What is Botanix Pharmaceuticals Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
41%

Over the last year, the Cash & Cash Equivalents growth was 674%. The average annual Cash & Cash Equivalents growth rates for Botanix Pharmaceuticals Ltd have been 54% over the past three years , 76% over the past five years , and 41% over the past ten years .

Back to Top